Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interpreting data in AML

P H Wiernik1

  • 1Albert Einstein Cancer Center/Montefiore Medical Center, Bronx, New York 10467-2401, USA.

Leukemia
|April 1, 1996
PubMed
Summary
This summary is machine-generated.

Advances in acute myeloid leukemia treatment include new drugs and supportive care, leading to better remission rates. Future research focuses on targeted therapies based on specific leukemia molecular features.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council.

Leukemia·1997
Same author

All-trans-retinoic acid in acute promyelocytic leukemia.

The New England journal of medicine·1997
Same author

Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study.

Blood·1997
Same author

RAR alpha1/RAR alpha2-PML mRNA expression in acute promyelocytic leukemia cells: a molecular and laboratory-clinical correlative study.

Blood·1997
Same author

A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia.

Leukemia research·1997
Same author

Intracranial Hodgkin's disease in two patients with familial Hodgkin's disease.

Medical and pediatric oncology·1997
Same journal

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026
Same journal

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same journal

Single-cell DNA methylation analysis uncovers epigenetic pathways in the transformation of MDS to AML.

Leukemia·2026
Same journal

PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.

Leukemia·2026
Same journal

Lineage-restricted dependency on an oncofetal SNHG29-IGF2BP1 RNA axis in acute megakaryoblastic leukemia.

Leukemia·2026
Same journal

Selective targeting of RSK signaling with PMD-026 suppresses FLT3-activated acute myeloid leukemia while sparing normal hematopoiesis.

Leukemia·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) treatment has evolved significantly since the 1960s.
  • Chemotherapy and supportive care, including antibiotics and colony-stimulating factors, have improved patient survival and remission rates.
  • Recent findings highlight differential responses of specific leukemic syndromes to interventions.

Purpose of the Study:

  • To review the progress in AML treatment.
  • To emphasize the importance of supportive care and recent therapeutic advances.
  • To outline future directions in AML therapy, focusing on molecularly targeted treatments.

Main Methods:

  • Review of historical and recent advancements in AML treatment.
  • Discussion of supportive care measures like antibiotics and colony-stimulating factors.

Related Experiment Videos

  • Exploration of emerging therapeutic strategies, including molecularly targeted therapy.

    • Main Results:

    • New drug activities contribute to curing approximately 20% of AML patients.
    • Supportive care enables patients to complete chemotherapy, achieving complete remission.
    • Colony-stimulating factors improve treatment delivery in high-risk patients during induction therapy.
    • Specific leukemic syndromes show dramatic responses to targeted interventions.

    Conclusions:

    • AML treatment has seen steady progress through drug development and supportive care.
    • Understanding the mechanisms behind differential responses is crucial for future therapy.
    • Molecularly targeted therapy, informed by unique molecular features of leukemic syndromes, represents the next frontier in AML treatment.
    • Antisense oligonucleotide research is an initial step towards developing targeted therapies.